Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Friedegund Meier

Showing results (81-90 of 234) with videos related to

Pageof 24
Sort By:
Cancer Immunology, Immunotherapy : CII|December 22, 2010
Survival after intratumoral interleukin-2 treatment of 72 melanoma patients and response upon the first chemotherapy during follow-upBenjamin Weide, Thomas Kurt Eigentler, Annette Pflugfelder, et al.
Plos One|December 7, 2013
Serum S100B, lactate dehydrogenase and brain metastasis are prognostic factors in patients with distant melanoma metastasis and systemic therapyBenjamin Weide, Sabina Richter, Petra Büttner, et al.
European Journal of Cancer (Oxford, England : 1990)|August 18, 2023
Practical guidelines for the management of adverse events of the T cell engager bispecific tebentafuspJessica C Hassel, Carola Berking, Andrea Forschner, et al.
Plos One|July 5, 2013
Melanoma patients with unknown primary site or nodal recurrence after initial diagnosis have a favourable survival compared to those with synchronous lymph node metastasis and primary tumourBenjamin Weide, Christine Faller, Margrit Elsässer, et al.
American Journal of Clinical Dermatology|February 9, 2018
Melanoma Brain Metastases: Local Therapies, Targeted Therapies, Immune Checkpoint Inhibitors and Their Combinations-Chances and ChallengesMarvin Kuske, Ricarda Rauschenberg, Marlene Garzarolli, et al.
Experimental Dermatology|June 26, 2003
Fibroblast growth factor-2 but not Mel-CAM and/or beta3 integrin promotes progression of melanocytes to melanomaFriedegund Meier, Ulrich Caroli, Kapaettu Satyamoorthy, et al.
The Journal of Investigative Dermatology|December 17, 2008
Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomideTobias Sinnberg, Konstantinos Lasithiotakis, Heike Niessner, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 4, 2024
Hereditary cutaneous leiomyomatosis and low-grade glioma due to a fumarate hydratase mutationJörg Laske, Matthias Meinhardt, Silke Reif, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|April 23, 2021
PET/CT in malignant melanoma: a two-tiered healthcare system? Updated healthcare situation regarding initial staging of malignant melanoma with PET/CTAntonia Matiszick, Charlyn Völker, Claus Garbe, et al.
Journal of the American Academy of Dermatology|June 25, 2011
Hazard rates for recurrent and secondary cutaneous melanoma: an analysis of 33,384 patients in the German Central Malignant Melanoma RegistryUlrike Leiter, Petra G Buettner, Thomas K Eigentler, et al.
Pageof 24

Showing results (81-90 of 234) with videos related to

Sort By:
Pageof 24
Cancer Immunology, Immunotherapy : CII|December 22, 2010
Survival after intratumoral interleukin-2 treatment of 72 melanoma patients and response upon the first chemotherapy during follow-upBenjamin Weide, Thomas Kurt Eigentler, Annette Pflugfelder, et al.
Plos One|December 7, 2013
Serum S100B, lactate dehydrogenase and brain metastasis are prognostic factors in patients with distant melanoma metastasis and systemic therapyBenjamin Weide, Sabina Richter, Petra Büttner, et al.
European Journal of Cancer (Oxford, England : 1990)|August 18, 2023
Practical guidelines for the management of adverse events of the T cell engager bispecific tebentafuspJessica C Hassel, Carola Berking, Andrea Forschner, et al.
Plos One|July 5, 2013
Melanoma patients with unknown primary site or nodal recurrence after initial diagnosis have a favourable survival compared to those with synchronous lymph node metastasis and primary tumourBenjamin Weide, Christine Faller, Margrit Elsässer, et al.
American Journal of Clinical Dermatology|February 9, 2018
Melanoma Brain Metastases: Local Therapies, Targeted Therapies, Immune Checkpoint Inhibitors and Their Combinations-Chances and ChallengesMarvin Kuske, Ricarda Rauschenberg, Marlene Garzarolli, et al.
Experimental Dermatology|June 26, 2003
Fibroblast growth factor-2 but not Mel-CAM and/or beta3 integrin promotes progression of melanocytes to melanomaFriedegund Meier, Ulrich Caroli, Kapaettu Satyamoorthy, et al.
The Journal of Investigative Dermatology|December 17, 2008
Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomideTobias Sinnberg, Konstantinos Lasithiotakis, Heike Niessner, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 4, 2024
Hereditary cutaneous leiomyomatosis and low-grade glioma due to a fumarate hydratase mutationJörg Laske, Matthias Meinhardt, Silke Reif, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|April 23, 2021
PET/CT in malignant melanoma: a two-tiered healthcare system? Updated healthcare situation regarding initial staging of malignant melanoma with PET/CTAntonia Matiszick, Charlyn Völker, Claus Garbe, et al.
Journal of the American Academy of Dermatology|June 25, 2011
Hazard rates for recurrent and secondary cutaneous melanoma: an analysis of 33,384 patients in the German Central Malignant Melanoma RegistryUlrike Leiter, Petra G Buettner, Thomas K Eigentler, et al.
Pageof 24